Throw the doors open, build your team, tell everyone. #S10e64
Play • 12 min
Throw the doors open, build your team, tell everyone. #S10e64

- New mom chat
- Kali’s article and twitter
- Tavillas: (6/22/15)


- Anglemans and Ionis!
- Praxis update: At the end, scroll down.

- Webinar was awesome
- Sign up!

- Assessment: -
- Webinar:
- Sponsored testing with Mahzi!

 - June 2022
 - Sign up for the EF Panel:

- MDBR: Join us and secure $30k matching funds
- MICE: Help us Make 2!

- June 25 in DFW - Join us for a family meeting and hear from Dr. Perry.  Link soon.
- September 12-14 in San Diego - #GlobalGenes Meeting.  Link soon.
- October 8 in NJ - Caren Leib Gala
- October 8 in SC - Scramble for SYNGAP
- November 12 in GA - Sparks of Hope Gala
- December 1 in TN - Syngap Science Meeting -

This is a podcast: subscribe to and rate this 10 minute #podcast #SYNGAP10 here
Apple podcasts:

Episode 64 of #Syngap10 - June 14, 2022
#F78A1 #Syngap #epilepsy #autism #intellectualdisability #id #anxiety #raredisease #epilepsyawareness #autismawareness #rarediseaseresearch #SynGAPResearchFund #CareAboutRare #PatientAdvocacy #GCchat #Neurology #GlobalCollaboration #EpilepsyFoundation #Praxis #ProbablyGenetic #Mahzi

Copy from letter from Praxis:
Monday morning, June 6th, we published an 8K filing announcing news involving multiple programs at Praxis Precision Medicines. One of these announcements pertained to the FDA’s clinical hold on our recent IND filing for PRAX-222 in SCN2A, so we wanted to share further context for it.

On May 25, 2022, the Company received a communication from the U.S. Food and Drug Administration (the “FDA”) providing additional information on the clinical hold placed on the Company’s Investigational New Drug application (the “IND”) for the study of PRAX-222, an antisense oligonucleotide, for the treatment of patients with SCN2A gain-of-function mutations. The communication indicated that our IND could be cleared once we submit additional documentation related to the preclinical non-human primate toxicology study that supports the proposed starting dose in the clinical study. We’re requesting a Type A meeting with the FDA to confirm the study design and further clarify the requirements for dose escalation beyond the starting dose. This surely will leave our SCN2A community with questions about the timing of our path forward. While the protocol and the discussions being held with the FDA remain confidential, we will do our best to maintain transparency and responsiveness throughout the process.

We continue to be fully committed to advancing PRAX-222 to clinical study. We also want to restate that this news is specific to PRAX-222, without impact on our PRAX-562 program for SCN2A, SCN8A and TSC. In Monday’s press release, we reiterated our focus on driving toward proof of concept for PRAX-562. We’ll provide further updates on PRAX-562 as we approach m


Send in a voice message:
More episodes
Clear search
Close search
Google apps
Main menu